Kiromic Biopharma, Inc. KRBP
We take great care to ensure that the data presented and summarized in this overview for Kiromic Biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in KRBP
Top Purchases
Top Sells
About KRBP
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Insider Transactions at KRBP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2024
|
Brian Hungerford CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+1.67%
|
$2,000
$2.6 P/Share
|
|
Jun 12
2024
|
Pamela Misajon Director |
BUY
Open market or private purchase
|
Direct |
1,610
+2.73%
|
$4,830
$3.27 P/Share
|
|
Jun 12
2024
|
Pietro Bersani CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+2.12%
|
$9,000
$3.28 P/Share
|
|
Jun 12
2024
|
Brian Hungerford CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+1.7%
|
$3,000
$3.18 P/Share
|
|
Jun 11
2024
|
Pietro Bersani CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+2.16%
|
$9,000
$3.23 P/Share
|
|
Jun 11
2024
|
Michael Nagel Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.26%
|
$3,000
$3.33 P/Share
|
|
Jun 10
2024
|
Pamela Misajon Director |
BUY
Open market or private purchase
|
Direct |
1,701
+5.89%
|
$3,402
$2.93 P/Share
|
|
May 03
2024
|
Brian Hungerford CFO |
BUY
Grant, award, or other acquisition
|
Direct |
56,933
+38.89%
|
-
|
|
May 03
2024
|
Pietro Bersani CEO |
BUY
Grant, award, or other acquisition
|
Direct |
45,968
+50.0%
|
-
|
|
Mar 18
2024
|
Michael Nagel Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+29.85%
|
-
|
|
Mar 18
2024
|
Pamela Misajon Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+41.38%
|
-
|
|
Mar 18
2024
|
Michael Catlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+41.38%
|
-
|
|
Aug 11
2022
|
Scott Dahlbeck Chief of Staff |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+9.14%
|
-
|
|
Aug 11
2022
|
Daniel Grant Clark Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+44.34%
|
-
|
|
Aug 11
2022
|
Pietro Bersani CEO |
BUY
Grant, award, or other acquisition
|
Direct |
638,298
+50.0%
|
-
|
|
May 23
2022
|
Scott Dahlbeck Chief of Staff |
BUY
Exercise of conversion of derivative security
|
Direct |
17,240
+3.72%
|
-
|
|
Sep 09
2021
|
Internati Maurizio Chiriva CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
2,800
+0.2%
|
$8,400
$3.7 P/Share
|
|
Jul 13
2021
|
Michael Charles Ryan Officer |
BUY
Other acquisition or disposition
|
Direct |
50,189
+50.0%
|
-
|
|
May 24
2021
|
Jerry A. Schneider Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$35,000
$7.31 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 157K shares |
|---|---|
| Open market or private purchase | 12.3K shares |